In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Oxygen therapy does not improve survival in patients with heart attack symptoms (DETO2X-AMI)



Barcelona, Spain – 28 Aug 2017: Oxygen therapy does not improve survival in patients with heart attack symptoms, according to late-breaking research presented today in a Hot Line LBCT Session at ESC Congress (1) and published in the NEJM.

“The DETO2X-AMI (2) study questions the current practice of routine oxygen therapy for all patients with suspected myocardial infarction (heart attack),” said first author Dr Robin Hofmann, a cardiologist from the Karolinska Institutet at Södersjukhuset, Stockholm, Sweden.

This prospective, randomised, open-label trial enrolled 6 229 patients with suspected heart attack from 35 hospitals across Sweden. Half of the patients were assigned to oxygen given through an open face mask and the other half to room air without a mask.

The primary outcome, the mortality rate one year after randomisation, was not statistically different between the two groups (5.0% in the oxygen group versus 5.1% in the air group). Similarly, there was no significant difference between the two groups for secondary endpoints, including the risk of a new heart attack or heart muscle injury measured by markers in the blood.

Even in patients at high risk, such as smokers, older patients, patients with diabetes, or patients with previous heart disease, the results were similar concerning mortality within one year.

European Society of Cardiology (ESC) guidelines on treatment of patients with ST-segment elevation myocardial infarction (STEMI) recommend oxygen (by mask or nasal prongs) for patients who are breathless, hypoxic, or have heart failure. (3) They add that the systematic use of oxygen in patients without heart failure or dyspnoea (shortness of breath) “is at best uncertain”.

“ESC guidelines have gradually shifted towards more restrictive use of oxygen,” said author Prof Stefan James, a cardiologist at Uppsala University, Uppsala, Sweden. “While the current recommendations were based on expert opinion only, we can now add substantial new data from our large clinical trial.”

“The study results will likely have an immediate impact on clinical practice and future guidelines,” he added. “Our findings do not support the routine use of oxygen therapy in all patients with symptoms of a heart attack. The general use of oxygen in these cases is still widespread in the world but can now be adjusted.”

A fear that oxygen therapy could be harmful arose after the AVOID trial found a larger infarct size in patients receiving oxygen therapy. (4) “Routine oxygen therapy seems unnecessary in this patient group, but fortunately our data do not give any indication of increased risk for the patients on oxygen,” said Prof James. “So all of us who have generally used oxygen for decades can now rest assured.”

The DETO2X-AMI trial is the first large-scale randomised trial of oxygen therapy in patients with suspected myocardial infarction to be large enough to reveal meaningful findings on mortality and morbidity. The study enrolled six times more patients than all previous randomised trials of this therapy combined and included a much broader range of patients to make the results relevant to everyday clinical practice.

The study’s registry-based randomised clinical trial protocol used national registries including SWEDEHEART for randomisation, case record forms and follow-up. Dr Hofmann said: “With this design we could enrol 6 629 patients with high quality data in less than three years and keep overall costs to a fraction of a conventional randomised trial.”

ENDS

Notes to editor

Sources of funding: The Swedish Heart-Lung Foundation, The Swedish Research Council and the Swedish Foundation for Strategic Research.

Disclosures: None.

References and notes
(1) The study “DETermination of the role of OXygen in suspected Acute Myocardial Infarction” will be presented during:
• The press conference Hot Line - Late Breaking Clinical Trials 2 on Monday 28 August from 09:00 to 10:00.
• The session Hot Line - Late Breaking Clinical Trials 2 on Monday 28 August from 11:00 to 12:45 in Barcelona – Main Auditorium.
(2) DETermination of the role of OXygen in suspected Acute Myocardial Infarction (DETO2X-AMI)
(3) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal. 2012;33:2569–2619. doi:10.1093/eurheartj/ehs215
(4) Stub D, et al. Air versus oxygen in ST-segment-elevation myocardial infarction. Circulation. 2015;131:2143–2150. doi: 10.1161/CIRCULATIONAHA.114.014494.


ESC Press Office
For more information, please contact the ESC Press Office: press@escardio.org.
For press enquiries, independent comment on-site, please contact, the Media & Press Coordinator Jacques Olivier COSTA: +34 666 509 856
The press conference timetable is available here.

To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.  

About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2017
ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2017 takes place 26 to 30 August at the Fira Gran Via in Barcelona, Spain. The scientific programme is here. More information is available from the ESC Press Office at press@escardio.org.

This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2017. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.